Executive interview – BiondVax Pharmaceuticals

Published on 17 December 2019

BiondVax Pharmaceuticals (Nasdaq: BVXV) is a clinical biopharmaceutical company developing a universal flu vaccine, known as M-001. M-001 is currently undergoing a pivotal, clinical efficacy, Phase III trial in about 12,400 participants, the results of which are expected by the end of 2020.

M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains. In six completed clinical trials to date, the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains.

Share this with friends and colleagues